← Back
Data updated: Mar 29, 2026
KYOWA KIRIN
OncologyNeurologyMetabolic
Biotech
KYOWA KIRIN is a biotechnology company focused on Oncology, Neurology, Metabolic. Key products include NOURIANZ.
1997
Since
4
Drugs
-
Trials
4
Approved (2yr)
Top Drug Revenues Pro
Loading...
Revenue Over Time Pro
Loading...
Recent Activity
POTELIGEO 2026-02-19
Labeling
CRYSVITA 2025-08-28
Labeling
POTELIGEO 2025-01-21
Labeling
FARESTON 2024-12-13
Labeling
SEC Filings
Pro
Loading...
Therapeutic Areas
Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5
Oncology 35%
1 drugs Phase 3: 1 Phase 2: 6 Phase 1: 12
Neurology 21%
1 drugs Phase 3: 1 Phase 2: 2 Phase 1: 6
Metabolic 20%
0 drugs Phase 3: 4 Phase 2: 1 Phase 1: 1
Immunology 19%
0 drugs Phase 3: 3 Phase 2: 1 Phase 1: 4
Gastroenterology 5%
0 drugs Phase 2: 1 Phase 1: 3
Pipeline Forecast
Loading...
Loading...
Upcoming Trial Milestones Pro
Loading...
Patent Cliff Pro
Loading...
Loading...
Loading...
Competitors by Therapeutic Area
Takeda big-pharma
Immunology, Oncology, Gastroenterology, Neurology, Metabolic
Eli Lilly big-pharma
Metabolic, Oncology, Immunology, Neurology
Amgen biotech
Oncology, Immunology, Metabolic, Gastroenterology, Neurology
EMD SERONO INC biotech
Oncology, Neurology, Immunology, Metabolic, Gastroenterology
Bristol-Myers Squibb big-pharma
Oncology, Immunology, Gastroenterology, Neurology